{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:40:16Z","timestamp":1791258016271,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":3371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1093\/annonc\/mdq422","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T07:47:43Z","timestamp":1287474463000},"page":"vii180-vii185","source":"Crossref","is-referenced-by-count":35,"special_numbering":"S7","title":["Prevention and treatment of side-effects of systemic treatment: bone loss"],"prefix":"10.1016","volume":"21","author":[{"given":"J.-J.","family":"Body","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq422_bb0010","first-page":"651","article-title":"Osteoporosis in breast and prostate cancer survivors","volume":"19","author":"Hoff","year":"2005","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdq422_bb0015","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-007-0439-4","article-title":"Management of cancer treatment-induced bone loss in early breast and prostatic cancer \u2013 a consensus paper of the Belgian Bone Club","volume":"18","author":"Body","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdq422_bb0020","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1016\/S0002-9343(97)90022-X","article-title":"The crippling consequences of fractures and their impact on quality of life","volume":"103","author":"Cooper","year":"1997","journal-title":"Am J Med"},{"key":"10.1093\/annonc\/mdq422_bb0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdq422_bb0030","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","article-title":"Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer","volume":"61","author":"Bruning","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq422_bb0035","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.ejca.2009.09.026","article-title":"The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer","volume":"45","author":"Hadji","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq422_bb0040","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","volume":"20","author":"Jonat","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0045","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0050","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ejca.2005.10.028","article-title":"Effects of third-generation aromatase inhibitors on bone","volume":"42","author":"McCloskey","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq422_bb0055","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1158\/1078-0432.CCR-04-0438","article-title":"Effects of the F(7) steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats","volume":"10","author":"Goss","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq422_bb0060","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ejca.2007.08.029","article-title":"Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women","volume":"43","author":"McCloskey","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq422_bb0065","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"on behalf of the ATAC Trialists\u2019 Group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdq422_bb0070","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","article-title":"Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomized placebo-controlled study","volume":"42","author":"Geisler","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq422_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0080","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0085","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq422_bb0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of clinical fracture after gonadotropin-releasing hormone agonist therapy for prostate cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdq422_bb0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq422_bb0100","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0105","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0115","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq422_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq422_bb0125","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2006.08.8054","article-title":"Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study","volume":"25","author":"Kaufmann","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","article-title":"Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment","volume":"95","author":"Hershman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdq422_bb0135","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0140","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdq422_bb0150","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq422_bb0155","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdq422_bb0165","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq422_bb0170","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdq422_bb0175","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0180","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdq422_bb0185","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq422_bb0190","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ucl.2004.01.001","article-title":"Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician","volume":"31","author":"Higano","year":"2004","journal-title":"Urol Clin North Am"},{"key":"10.1093\/annonc\/mdq422_bb0195","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ucl.2004.02.002","article-title":"The impact of osteoporosis in men treated for prostate cancer","volume":"31","author":"Oefelein","year":"2004","journal-title":"Urol Clin North Am"},{"key":"10.1093\/annonc\/mdq422_bb0200","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","article-title":"Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer","volume":"166","author":"Oefelein","year":"2001","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdq422_bb0205","first-page":"3551","article-title":"Osteoporosis and fractures after androgen deprivation initiation for prostate cancer","volume":"14","author":"Malcolm","year":"2007","journal-title":"Can J Urol"},{"key":"10.1093\/annonc\/mdq422_bb0210","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0215","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2008","journal-title":"J Urol"},{"issue":"Suppl 11","key":"10.1093\/annonc\/mdq422_bb0220","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","article-title":"Dosing regimens and main adverse events of bisphosphonates","volume":"28","author":"Body","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdq422_bb0225","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw \u2013 do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341939725X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341939725X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/suppl_7\/vii180\/486297\/mdq422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T18:16:48Z","timestamp":1635790608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341939725X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":44,"alternative-id":["S092375341939725X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq422","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}